capecitabine has been researched along with imatinib mesylate in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (21.43) | 29.6817 |
| 2010's | 11 (78.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Kaplow, R | 1 |
| Curtiss, FR | 1 |
| Albain, K; Barlow, WE; Chew, HK; Gown, A; Gralow, J; Hayes, DF; Hortobagyi, GN; Lew, D; Livingston, R | 1 |
| Blobe, GC; Dugan, E; Favaro, J; Fernando, NH; Hurwitz, HI; Meadows, KL; Morse, MA; Nixon, AB; Petros, WP; Truax, R | 1 |
| Bugnon, O; Jeanneret, LA; Lüthi, F; Schneider, MP; Troxler, S | 1 |
| Beckeringh, JJ; Boven, E; Hugtenburg, JG; Timmers, L; van Herk-Sukel, MP | 1 |
| Becker, K; Belle, S; Ebert, MP; Hofheinz, R; Krause, A; Mayr, M; Röcken, C; Schmid, RM; Schulte, N | 1 |
| Arnold, D; Hacker, UT; Hallek, M; Hinke, A; Hochhaus, A; Hoehler, T; Hofheinz, R; Kanzler, S; Moehler, MH; Schimanski, C; Seufferlein, T; Siebler, J; von Wichert, G | 1 |
| Aaron, M; Halperin, DM; Hoff, AO; Hoff, PM; Phan, AT; Yao, JC | 1 |
| Bláha, L; Isidori, M; Piscitelli, C; Russo, C; Smutná, M | 1 |
| Allaoui, M; Elm'hadi, C; Errihani, H; Ichou, M; Khmamouche, MR; Mahtat, E; Messaoudi, N; Oukabli, M; Tanz, R; Toreis, M | 1 |
| Alas, V; Boulanger, L; Goertz, HP; Reyes, C; Stokes, M; Xia, Y | 1 |
| Chen, B; Duan, G; Fan, H; Liu, Z; Qian, X; Tu, J; Zhou, Y | 1 |
1 review(s) available for capecitabine and imatinib mesylate
| Article | Year |
|---|---|
Innovations in antineoplastic therapy.
Topics: Adjuvants, Immunologic; Alemtuzumab; Aminoglycosides; Anastrozole; Androstadienes; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Agents; Arsenic Trioxide; Arsenicals; Benzamides; Bile; Boronic Acids; Bortezomib; Capecitabine; Cetuximab; Decanoic Acids; Deoxycytidine; Docetaxel; Drug Approval; Estradiol; Fluorouracil; Fulvestrant; Gefitinib; Gemtuzumab; Humans; Imatinib Mesylate; Letrozole; Leuprolide; Nitriles; Oligopeptides; Organoplatinum Compounds; Oxaliplatin; Oxides; Piperazines; Polyesters; Pyrazines; Pyrimidines; Quinazolines; Taxoids; Thionucleotides; Tissue Extracts; Triazoles; United States; United States Food and Drug Administration; Vidarabine Phosphate | 2005 |
5 trial(s) available for capecitabine and imatinib mesylate
| Article | Year |
|---|---|
A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Synergism; Female; Fluorouracil; Humans; Imatinib Mesylate; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Receptors, Platelet-Derived Growth Factor | 2008 |
A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Becaplermin; Benzamides; Capecitabine; Cohort Studies; Deoxycytidine; Drug Administration Schedule; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Middle Aged; Neoplasms; Neovascularization, Physiologic; Piperazines; Platelet-Derived Growth Factor; Proto-Oncogene Proteins c-sis; Pyrimidines; Skin | 2010 |
Phase I study of imatinib, cisplatin and 5-fluoruracil or capecitabine in advanced esophageal and gastric adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Cisplatin; Deoxycytidine; Esophageal Neoplasms; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Stomach Neoplasms | 2012 |
Phase I/II trial of capecitabine and oxaliplatin in combination with bevacizumab and imatinib in patients with metastatic colorectal cancer: AIO KRK 0205.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Bevacizumab; Capecitabine; Colorectal Neoplasms; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Middle Aged; Organoplatinum Compounds; Oxaliplatin; Piperazines; Prospective Studies; Pyrimidines; Treatment Outcome | 2013 |
A phase I study of imatinib, dacarbazine, and capecitabine in advanced endocrine cancers.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Dacarbazine; Deoxycytidine; Disease-Free Survival; Drug Administration Schedule; Endocrine Gland Neoplasms; Female; Fluorouracil; Humans; Imatinib Mesylate; Male; Middle Aged; Piperazines; Pyrimidines; Treatment Outcome | 2014 |
8 other study(ies) available for capecitabine and imatinib mesylate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Pharmacy benefit spending on oral chemotherapy drugs.
Topics: Administration, Oral; Ambulatory Care; Antineoplastic Agents; Benzamides; Benzenesulfonates; Capecitabine; Dasatinib; Deoxycytidine; Drug Costs; Employer Health Costs; Erlotinib Hydrochloride; Fluorouracil; Gefitinib; Health Benefit Plans, Employee; Humans; Imatinib Mesylate; Indoles; Insurance, Pharmaceutical Services; Lenalidomide; Neoplasms; Niacinamide; Phenylurea Compounds; Piperazines; Prescription Fees; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Sorafenib; Sunitinib; Thalidomide; Thiazoles; United States | 2006 |
[Therapeutic adherence to oral cancer therapy and interdisciplinary management].
Topics: Adenocarcinoma; Administration, Oral; Aged; Algorithms; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Capecitabine; Cecal Neoplasms; Deoxycytidine; Female; Fluorouracil; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Interdisciplinary Communication; Male; Medication Adherence; Neoplasms; Outpatients; Patient-Centered Care; Pharmacists; Physician's Role; Pilot Projects; Piperazines; Prospective Studies; Pyrimidines; Switzerland; Time Factors; Treatment Outcome | 2011 |
Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008.
Topics: Administration, Oral; Antineoplastic Agents; Benzamides; Capecitabine; Deoxycytidine; Fluorouracil; Humans; Imatinib Mesylate; Neoplasms; Netherlands; Pharmacies; Piperazines; Protein-Tyrosine Kinases; Pyrimidines | 2012 |
Teratogenic effects of five anticancer drugs on Xenopus laevis embryos.
Topics: Abnormalities, Drug-Induced; Animals; Antineoplastic Agents; Biological Assay; Capecitabine; Cisplatin; Embryo, Nonmammalian; Embryonic Development; Etoposide; Fluorouracil; Imatinib Mesylate; Teratogens; Toxicity Tests; Xenopus laevis | 2016 |
Successful management of synchronous recurrent breast carcinoma with chronic myelogenous leukemia: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Docetaxel; Female; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Neoplasm Recurrence, Local; Taxoids; Treatment Outcome | 2017 |
Impact of pharmacy channel on adherence to oral oncolytics.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Capecitabine; Erlotinib Hydrochloride; Female; Humans; Imatinib Mesylate; Male; Medicare; Medication Adherence; Middle Aged; Pharmaceutical Services; Pharmacies; Retrospective Studies; United States | 2017 |
Development and validation of a sensitive method for alkyl sulfonate genotoxic impurities determination in drug substances using gas chromatography coupled to triple quadrupole mass spectrometry.
Topics: Alkanesulfonates; Capecitabine; Drug Contamination; Gas Chromatography-Mass Spectrometry; Imatinib Mesylate; Limit of Detection; Mutagens; Reproducibility of Results; Solubility; Solvents; Tandem Mass Spectrometry | 2019 |